Shaping the future of cancer care
10 Apr 2024
Multiple myeloma is a blood cancer that develops in plasma cells in the bone marrow. Binding Site details how it is working with partners to raise awareness of multiple myeloma, and highlights how early recognition of the symptoms and confirmation of the diagnosis, and early referrals to hematologists and cancer care have the potential to improve the overall survival and quality of life for patients.
About the company
Binding Site
Binding Site, part of Thermo Fisher Scientific, is committed to improving patient lives worldwide through education, collaboration and innovation
Binding Site provide diagnostic solutions that help doctors, clinicians and laboratory researchers across the globe diagnose and monitor blood cancers and immune system disorders.
Founded by researchers at the University of Birmingham, Binding Site has continued to build on its strong scientific foundations, supporting research and development within our field and responding to the changing needs of patients, researchers and clinicians for over 30 years.
We are committed to working in collaboration with our partners and customers to lead the way in specialised medical diagnostics, ensuring we continue to make a difference together.
Related products
Request Quote for All Products
Optilite® - Optimised Protein System
Binding SiteThe robust and proven analyzer from The Binding Site, bringing you a reliable and optimized solution for special protein testing.
